Lisa Szymkowicz

Ms. Lisa Szymkowicz

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
LSLisa Szymkowicz
Lisa Szymkowicz
DWDerek Wilson
Derek Wilson
DJD. Andrew James
D. Andrew James

28 October 2021 in Toxins
Verified
Journal Article
Open access
PDF file
LSLisa Szymkowicz
Lisa Szymkowicz
JGJeffery Gerard
Jeffery Gerard
BMBenjamin Messham
Benjamin Messham
WTWai Wan Vivian Tam
Wai Wan Vivian Tam
DJD. Andrew James
D. Andrew James
The antigens for acellular pertussis vaccines are made up of protein components that are purified directly from Bordetella pertussis (B. pertussis) bacterial fermentation. As such, there are additional B. pertussis toxins that must be monitored as residuals during process optimization. This paper describes a liquid chromatography mass spectrometry (LC-MS) method for simultaneous analysis of residual protein toxins adenylate cyclase toxin (ACT) and dermonecrotic toxin (DNT), as well as a small molecule glycopeptide, tracheal cytotoxin (TCT) in a Pertussis toxin vaccine antigen. A targeted LC-MS technique called multiple reaction monitoring (MRM) is used for quantitation of ACT and TCT, which have established limits in drug product formulations. However, DNT is currently monitored in an animal test, which does not have an established quantitative threshold. New approaches for DNT testing are discussed, including a novel standard based on concatenated quantitation sequences for ACT and DNT. Collectively, the method represents a “3-in-1” analytical simplification for monitoring process-related residuals during development of B. pertussis vaccines.